Beam Therapeutics' pipeline, especially BEAM-101 for sickle cell disease, shows promise but remains in early stages with significant risks and high market expectations. Financially, BEAM has a strong ...
Beam Therapeutics Inc.’s base editing platform with BEAM-101 has trait-like hematology and RMAT/ODD designations. BEAM thinks this could eventually position it with a potential best-in-class SCD drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results